Iovance Biotherapeutics secured conditional approval for its drug Amtagvi in Australia, marking an expansion into high prevalence markets.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics secured conditional approval for its drug Amtagvi in Australia, marking an expansion into high prevalence markets.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Therapeutic Goods Administration
regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.